SEMULOPARIN DATA AT ASCO 11 – Exploiting the gap through SAVE ONCO
Clinical data from the SAVE-ONCO study on semuloparin is positive, but the commercial potential depends on its relative benefits over existing anticoagulants in the market, which are currently extensively used, despite the indication not being on their label. The SAVE-ONCO study was the first of its kind in terms of the size and type of cancer patients that were recruited, but being placebo controlled, it is difficult to gauge, how it fares in comparison to the current standard of care (Lovenox /dalterparin). Lovenox/dalteparin/nadroparin have shown robust efficacy in terms of VTE prevention in cancer population in a number of clinical studies.
COMPANIES MENTIONED
SANOFI, SAN
SANOFI, SAN
